Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

Fidder, H.; Schnitzler, F.; Ferrante, M.; Noman, M.; Katsanos, K.; Segaert, S.; Henckaerts, L.; Van Assche, G.; Vermeire, S.; Rutgeerts, P.
April 2009
Gut;Apr2009, Vol. 58 Issue 4, p501
Academic Journal
Background and aims: This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The medical records of 734 patients with IBD treated with infliximab and 666 control patients not treated with infliximab were reviewed for adverse events. The time of onset and outcome, severity and concomitant medication were recorded. Results: Patients and controls were followed up for serious adverse events for a median time of 58 months (IQR 33-88) and 144 months (IQR 83-163), respectively. 112 severe adverse events occurred in 93 patients (13%) treated with infliximab and 157 occurred in 126 (19%) control patients (OR 1.33 (95% CI 0.56 to 3.00, p = 0.45). There was no difference between the two groups in mortality, malignancies and infection rate. Tuberculosis was diagnosed in two patients receiving infliximab who had negative skin tests at baseline whereas none of 16 patients with positive skin tests who received prophylaxis developed tuberculosis. Concomitant treatment with steroids was the only independent risk factor for infections in patients treated with infliximab (OR 2.69 (95% CI 1.18 to 6.12), p = 0.018). The most commonly observed systemic side effects were skin eruptions including psoriasiform eruptions in 150 patients (20%). Conclusions: Long-term infliximab treatment had a good overall safety profile in the patient cohort studied.


Related Articles

  • Identifying complications of interventional procedures from UK routine healthcare databases: a systematic search for methods using clinical codes. Keltie, Kim; Cole, Helen; Arber, Mick; Patrick, Hannah; Powell, John; Campbell, Bruce; Sims, Andrew // BMC Medical Research Methodology;2014, Vol. 14 Issue 1, p1 

    Background Several authors have developed and applied methods to routine data sets to identify the nature and rate of complications following interventional procedures. But, to date, there has been no systematic search for such methods. The objective of this article was to find, classify and...

  • Comp rules on epidural injections may tighten. GOLDBERG, STEPHANIE // Business Insurance;12/22/2014, Vol. 48 Issue 26, p0004 

    The article reports on the possible tightening of guidelines on epidural steroid injections for radicular pain treatment by state workers compensation systems and payers amid warnings raised by the U.S. Food and Drug Administration (FDA). It mentions concerns over the injections including their...

  • Capecitabine.  // Reactions Weekly;5/5/2012, Issue 1400, p12 

    A reference entry for a case of an adverse reaction to capecitabine is presented.

  • Temozolomide.  // Reactions Weekly;8/31/2013, Issue 1467, p35 

    The article discusses the case report of an 8-year-old girl who developed acute myelotoxicity while receiving temozolomide for metastatic diffuse intrinsic pontine glioma.

  • Gemcitabine.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p141 

    The article presents a case study of a 58-year-old male patient who developed thrombotic thrombocytopenic purpura (TTP) and haemolytic uraemic syndrome (HUS) following the administration of gemcitabine.

  • Flupentixol/olanzapine/sulpiride/thioridazine.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p138 

    The article presents a case study of a 28-year-old male patient who pathological gambling during therapy with flupentixol, thioridazine, olanzapine and sulpiride.

  • Ioversol.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p170 

    The article presents a case study of a 74-year old female patient who developed pulmonary oedema due to ioversol contrast.

  • Influenza A virus vaccine H1N1.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p167 

    The article presents case studies of 23 female patients who developed pregnancy-related adverse reactions including spontaneous abortion, stillbirth, premature delivery, ectopic pregnancy, and uterine contractions following administration of Influenza A virus vaccine H1N1.

  • Iguratimod.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p155 

    The article presents a case study of a patient who developed disorder of liver function during treatment with iguratimod.


Read the Article


Sign out of this library

Other Topics